Zurich-based cloud-based platform for healthcare industry, Rivia, has raised €3 million in a seed round led by Austrian VC Speedinvest. Nina Capital and Amino Collective also joined the funding.
- Rivia was founded in 2022 by Erik Scalfaro and Tiago Kielige. The startup develops an analytics and clinical trial data infrastructure powered by AI for biotech companies. Rivia presents a platform with interactive analytics and AI-driven data insights to simplify the collection and comprehension of clinical trial data.
- The leading investor in this round is Speedinvest, one of the most active investors in Europe. It has recently invested in Dutch home-building platform Haaven in a round, where the startup raised €1.1 million.
“Rivia’s infrastructure and AI-powered platform fundamentally change how biotech companies access and analyze their clinical trial data, glean insights, and make real-time decisions. The feedback from their customers is phenomenal, and we believe Rivia has the potential to become the gold standard in the industry,” said Andrea Zitna, partner with Speedinvest’s health and techbio team.
- With the fresh funding, Rivia plans to grow its team and boost the creation of new products.
